Valuation: Cellectar Biosciences Inc

Market Cap 8M 7.29M 6.72M 6.11M 11.46M 741M 12.04M 81.73M 32.48M 405M 30.02M 29.39M 1.27B P/E 2026 *
-0.35x
P/E 2027 * -0.39x
Enterprise Value 8M 7.29M 6.72M 6.11M 11.46M 741M 12.04M 81.73M 32.48M 405M 30.02M 29.39M 1.27B EV / Sales 2026 *
-
EV / Sales 2027 * 3.11x
Free-Float
98.35%
Yield 2026 *
-
Yield 2027 * -
11-10 Cellectar Biosciences, Inc., Q3 2026 Earnings Call, Nov 10, 2026
11-10 Cellectar Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
11-04 Cellectar Biosciences Announces Updated Clinical Data and Phase 3 Trial Design for Iopofosine I 131 in Waldenstro¨m Macroglobulinemia CI
10-27 Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated With Iopofosine I 131 CI
10-15 Cellectar Biosciences, Inc. Presents Efficacy Results From Phase 2b CLOVER WaM Subset Analysis Of Iopofosine I 131 In Patients Relapsed/Refractory To BTK Inhibitor Therapy CI
09-29 Cellectar Biosciences Announces Subset Analysis of Data from Phase 2 Clover Wam Clinical Trial of iopofosine I 131 in Patients Refractory or Resistant to BTK Inhibitor Therapy CI
08-18 Cellectar Biosciences, Inc. - Special Call
08-13 Cellectar Biosciences, Inc., Q2 2026 Earnings Call, Aug 13, 2026
08-13 Cellectar Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
06-01 Cellectar Biosciences Highlights New Efficacy Data from Phase 2B Clover Wam Study of Iopofosine I 131 in Relapsed or Refractory Waldenström Macroglobulinemia CI
05-20 Cellectar Biosciences Files for Secondary Offering of Common Shares MT
05-18 Cellectar Biosciences, Inc. Announces Board Changes CI
05-14 Cellectar Biosciences, Inc., Q1 2026 Earnings Call, May 14, 2026
Manager TitleAgeSince
Chief Executive Officer 67 15/06/2015
Director of Finance/CFO 61 28/05/2014
Chief Operating Officer 53 23/02/2022
Director TitleAgeSince
Director/Board Member 57 01/02/2008
Director/Board Member 67 15/06/2015
Chairman 56 01/08/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.30%-6.68%+27.12%+127.32% 1,200B
+1.25%-5.35%+32.65%+78.98% 651B
+0.94%-2.99%+21.13%+106.30% 506B
-0.60%-1.95%+25.73%+67.00% 377B
+0.69%-9.50%+36.78%+30.83% 330B
+0.41%-4.70%+24.18%+50.18% 288B
+0.81%-4.08%-2.95%+31.59% 272B
-0.15%-6.45%+29.06%+65.76% 236B
-0.06%-0.98%+31.42%+122.83% 206B
Average +0.33%-4.76%+25.01%+75.64% 452B
Weighted average by Cap. +0.30%-5.19%+26.02%+87.88%

Financials

2026 *2027 *
Net sales - 2.58M 2.35M 2.16M 1.97M 3.69M 238M 3.88M 26.3M 10.45M 130M 9.66M 9.46M 409M
Net income -30.16M -27.47M -25.31M -23.02M -43.19M -2.79B -45.39M -308M -122M -1.53B -113M -111M -4.79B -41.9M -38.16M -35.17M -31.99M -60.01M -3.88B -63.07M -428M -170M -2.12B -157M -154M -6.65B
Net Debt - -
Logo Cellectar Biosciences Inc
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cellectar Biosciences Inc